Free Virtual Consultation 3
One such molecule is the microglial cell surface receptor TREM2 (triggering receptor expressed on myeloid cells 2), which recognizes misfolded proteins like amyloid and activates microglia to clear them
The participants were divided into the following experimental groups or a placebo group: 1 mg of retatrutide (subcutaneously) 4 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 4 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 12 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg Here are the detailed results of the trial at 24 weeks and 48 weeks: Phase II clinical trial projects promising results of retatrutide in weight management
Funding This work was supported by grants from National Natural Science Foundation of China (U23A20410), Young and Middle-aged Scientific Research Major Project of Fujian Provincial Health Commission (2021ZQNZD004), Joint Funds for the innovation of Science and Technology of Fujian province (2021Y9100)
It may take several weks of treatment to notice improvement of condition
Improves Clarity: Fades blemishes, hyperpigmentation, and sun spots for a clearer complexion
